	Application No.	Applicant(s)
Notice of Allowability		
	10/735,008 Examiner	CHENG ET AL.
	Examiner	Artonit
	Tekchand Saidha	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to 12/21/2006.		
2. The allowed claim(s) is/are <u>1-3,7-10,14 and 16</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received. 2. Contified application of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	•	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal I	Potent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	• •
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Da 7. ⊠ Examiner's Amend	ate
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit		nent of Reasons for Allowance
of Biological Material		ient of Reasons for Allowance
	9. 🔲 Other	

Art Unit: 1652

Notice of Allowability

- 1. Applicants' amendment and arguments filed December 21, 2006 in response to Non-Final Office Action mailed June 30, 2006 is acknowledged.
- 2. Applicants arguments were considered in the light of the amendment to the claims and the availability of numerous genes encoding the upper and lower isoprenoid pathway in the Genbank (Tables 2 & 3), and were found to persuasive, allowing the rejections under 112 first paragraph (enablement and written) be withdrawn.
- 3. Claims 1-3 & 7-16 are present and under consideration in this application.
- 4. Claims 1-3, 7-10, 14 & 16 are allowed, subject to the following Examiner's Amendment.
- 5. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was not required.

This application is in condition for allowance except for the presence of claims 11-13 & 15, non-elected without traverse.

Accordingly, claims 11-13 & 15 are canceled.

Amend claims as follows (typographical):

Claims 2, 7, 8, 9, 10, 14 & 16, recite the word 'Claim or Claims' with an uppercase 'C' in the middle of a sentence.

Delete the uppercase 'C' in the middle of a sentence for all these claims, and replace with a lowercase 'C'.

Application/Control Number: 10/735,008 Page 3

Art Unit: 1652

6. The following is an examiner's statement of reasons for allowance:

In view of the claim(s) amendments, Applicants' arguments and the cancellation of claims by the Examiner's amendment, the the carotenoid overproducing *E. coli* comprising genes encoding a functional isoprenoid enzymatic biosynthetic pathway and a disrupted dead gene and method of producing carotenoid(s) using these constructs are enabled, described, unobvious and patentable.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha (Ph.D.) whose telephone number is (571) 272-0940. The examiner can normally be reached on Monday-Friday from 8:15 am to 4:45 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy, can be reached at (571) 272-0928. The fax phone number for this Group in the Technology Center is 703 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is 571 272-1600.

Tekchánd Saidha

Primary Examiner, Art Unit 1652

Recombinant Enzymes, 02A65 Remsen Bld.

400 Dulany Street, Alexandria, VA 22314

Telephone: (571) 272-0940

January 23, 2007